Electromed (ELMD)
Market Price (5/27/2026): $38.49 | Market Cap: $316.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
Electromed (ELMD)
Market Price (5/27/2026): $38.49Market Cap: $316.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, and Remote Patient Monitoring. | Trading close to highsDist 52W High is -0.7%, Dist 3Y High is -0.7% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 31x Key risksELMD key risks include [1] adverse changes in healthcare reimbursement policies, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, and Remote Patient Monitoring. |
| Trading close to highsDist 52W High is -0.7%, Dist 3Y High is -0.7% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 31x |
| Key risksELMD key risks include [1] adverse changes in healthcare reimbursement policies, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Electromed (ELMD) stock has gained about 30% since 1/31/2026 because of the following key factors:
1. Record-breaking Q3 Fiscal 2026 Financial Performance: Electromed reported record net revenues of $18.6 million for Q3 FY2026, an 18.4% increase year-over-year, significantly surpassing consensus estimates of $17.6 million to $17.82 million. The company also achieved a diluted earnings per share (EPS) of $0.35, marking a 58.8% increase from the prior year and substantially beating analyst expectations of $0.25 to $0.26 per share. This quarter represented the 14th consecutive period of year-over-year revenue and profit growth.
2. Significant Operating Income Growth and Margin Expansion: The company demonstrated strong operational efficiency in Q3 FY2026, with operating income surging by 76.0% to a record $3.8 million. Concurrently, the gross margin improved to 78.8%. This substantial increase in profitability, outpacing revenue growth, indicates strong operating leverage.
Show more
1. Record-breaking Q3 Fiscal 2026 Financial Performance: Electromed reported record net revenues of $18.6 million for Q3 FY2026, an 18.4% increase year-over-year, significantly surpassing consensus estimates of $17.6 million to $17.82 million. The company also achieved a diluted earnings per share (EPS) of $0.35, marking a 58.8% increase from the prior year and substantially beating analyst expectations of $0.25 to $0.26 per share. This quarter represented the 14th consecutive period of year-over-year revenue and profit growth.
2. Significant Operating Income Growth and Margin Expansion: The company demonstrated strong operational efficiency in Q3 FY2026, with operating income surging by 76.0% to a record $3.8 million. Concurrently, the gross margin improved to 78.8%. This substantial increase in profitability, outpacing revenue growth, indicates strong operating leverage.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 28.2% change in ELMD stock from 1/31/2026 to 5/26/2026 was primarily driven by a 13.7% change in the company's Net Income Margin (%).| (LTM values as of) | 1312026 | 5262026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.87 | 38.30 | 28.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 66 | 72 | 8.4% |
| Net Income Margin (%) | 12.4% | 14.1% | 13.7% |
| P/E Multiple | 30.3 | 31.1 | 2.7% |
| Shares Outstanding (Mil) | 8 | 8 | 1.4% |
| Cumulative Contribution | 28.2% |
Market Drivers
1/31/2026 to 5/26/2026| Return | Correlation | |
|---|---|---|
| ELMD | 28.2% | |
| Market (SPY) | 8.8% | 23.9% |
| Sector (XLV) | -3.6% | 20.1% |
Fundamental Drivers
The 59.2% change in ELMD stock from 10/31/2025 to 5/26/2026 was primarily driven by a 19.6% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 5262026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.06 | 38.30 | 59.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 64 | 72 | 12.1% |
| Net Income Margin (%) | 11.8% | 14.1% | 19.6% |
| P/E Multiple | 26.6 | 31.1 | 17.0% |
| Shares Outstanding (Mil) | 8 | 8 | 1.5% |
| Cumulative Contribution | 59.2% |
Market Drivers
10/31/2025 to 5/26/2026| Return | Correlation | |
|---|---|---|
| ELMD | 59.2% | |
| Market (SPY) | 10.7% | 17.2% |
| Sector (XLV) | 3.8% | 20.3% |
Fundamental Drivers
The 66.3% change in ELMD stock from 4/30/2025 to 5/26/2026 was primarily driven by a 24.2% change in the company's Net Income Margin (%).| (LTM values as of) | 4302025 | 5262026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.03 | 38.30 | 66.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 60 | 72 | 20.3% |
| Net Income Margin (%) | 11.3% | 14.1% | 24.2% |
| P/E Multiple | 28.7 | 31.1 | 8.5% |
| Shares Outstanding (Mil) | 8 | 8 | 2.6% |
| Cumulative Contribution | 66.3% |
Market Drivers
4/30/2025 to 5/26/2026| Return | Correlation | |
|---|---|---|
| ELMD | 66.3% | |
| Market (SPY) | 36.9% | 23.7% |
| Sector (XLV) | 7.6% | 29.9% |
Fundamental Drivers
The 249.8% change in ELMD stock from 4/30/2023 to 5/26/2026 was primarily driven by a 195.7% change in the company's Net Income Margin (%).| (LTM values as of) | 4302023 | 5262026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.95 | 38.30 | 249.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 44 | 72 | 63.8% |
| Net Income Margin (%) | 4.8% | 14.1% | 195.7% |
| P/E Multiple | 44.3 | 31.1 | -29.8% |
| Shares Outstanding (Mil) | 8 | 8 | 2.8% |
| Cumulative Contribution | 249.8% |
Market Drivers
4/30/2023 to 5/26/2026| Return | Correlation | |
|---|---|---|
| ELMD | 249.8% | |
| Market (SPY) | 87.5% | 19.3% |
| Sector (XLV) | 16.9% | 19.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELMD Return | 33% | -19% | 4% | 171% | -1% | 31% | 290% |
| Peers Return | 4% | -15% | -8% | -24% | 38% | -15% | -27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| ELMD Win Rate | 75% | 50% | 58% | 75% | 42% | 60% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 42% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ELMD Max Drawdown | -25% | -34% | -32% | -24% | -49% | -23% | |
| Peers Max Drawdown | -33% | -44% | -52% | -42% | -36% | -55% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, ALMR, POAS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/26/2026 (YTD)
How Low Can It Go
| Event | ELMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.1% | -18.8% |
| % Gain to Breakeven | 51.8% | 23.1% |
| Time to Breakeven | 211 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -14.1% | -9.5% |
| % Gain to Breakeven | 16.5% | 10.5% |
| Time to Breakeven | 2 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -15.4% | -6.7% |
| % Gain to Breakeven | 18.1% | 7.1% |
| Time to Breakeven | 48 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -32.2% | -24.5% |
| % Gain to Breakeven | 47.4% | 32.4% |
| Time to Breakeven | 212 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.9% | -33.7% |
| % Gain to Breakeven | 72.0% | 50.9% |
| Time to Breakeven | 7 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -24.8% | -19.2% |
| % Gain to Breakeven | 33.1% | 23.8% |
| Time to Breakeven | 264 days | 105 days |
In The Past
Electromed's stock fell -34.1% during the 2025 US Tariff Shock. Such a loss loss requires a 51.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ELMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -34.1% | -18.8% |
| % Gain to Breakeven | 51.8% | 23.1% |
| Time to Breakeven | 211 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -32.2% | -24.5% |
| % Gain to Breakeven | 47.4% | 32.4% |
| Time to Breakeven | 212 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -41.9% | -33.7% |
| % Gain to Breakeven | 72.0% | 50.9% |
| Time to Breakeven | 7 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -24.8% | -19.2% |
| % Gain to Breakeven | 33.1% | 23.8% |
| Time to Breakeven | 264 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -24.9% | -3.7% |
| % Gain to Breakeven | 33.2% | 3.9% |
| Time to Breakeven | 96 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -28.1% | -0.2% |
| % Gain to Breakeven | 39.1% | 0.2% |
| Time to Breakeven | 105 days | 1 days |
In The Past
Electromed's stock fell -34.1% during the 2025 US Tariff Shock. Such a loss loss requires a 51.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Electromed (ELMD)
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
AI Analysis | Feedback
Here are 1-3 brief analogies for Electromed (ELMD):
ResMed for airway clearance therapy.
Dexcom for lung health.
AI Analysis | Feedback
- SmartVest Airway Clearance System: A line of products that apply high frequency chest wall oscillation (HFCWO) therapy for pulmonary care.
- SmartVest SQL System: Comprises an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose for delivering HFCWO therapy.
- SmartVest Connect: A wireless technology featuring a personalized HFCWO therapy management portal.
- Single Patient Use SmartVest and SmartVest Wrap products: Products designed for healthcare providers for use in acute care settings.
AI Analysis | Feedback
Electromed (ELMD) primarily sells its airway clearance therapy products to individuals. The company serves patients with various pulmonary conditions who require high-frequency chest wall oscillation (HFCWO) therapy. Its major customer categories are:
- Patients with Bronchiectasis
- Patients with Cystic Fibrosis
- Patients with Neuromuscular Disease
AI Analysis | Feedback
null
AI Analysis | Feedback
Jim Cunniff, President and Chief Executive Officer
Mr. Cunniff was appointed President and CEO of Electromed, effective July 1, 2023. He brings over 30 years of executive leadership experience in the MedTech and broader healthcare industry. Previously, he served as President, CEO, and Board Director for Leiters, Senior Vice President of Americas for Kinetics Concepts, and President of Emerging Markets for Stryker Corporation. Mr. Cunniff also served as President, Chief Executive Officer, and Board Director of Provista, a Vizient company, where he consistently grew revenue, executed two acquisitions, and shaped the strategic plan for the company.
Brad Nagel, Chief Financial Officer
Mr. Nagel has served as the Chief Financial Officer at Electromed since November 2022. He possesses over 15 years of financial leadership and strategic planning experience, including roles with Fortune 500 companies. Prior to joining Electromed, he was the Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic.
Christopher Holland, Chief Commercial Officer
Mr. Holland became the Chief Commercial Officer of Electromed in February 2022. He has 30 years of experience in driving commercial growth within Medical Technology markets. His previous roles include Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., and Chief Commercial Officer and Executive Vice President of Sales and Global Business Development at Nonin Medical, Inc.
Kristine Owata, Vice President of Reimbursement & Payer Relations
Ms. Owata has been the Vice President of Reimbursement & Payer Relations at Electromed since October 2020. She has over 15 years of diverse leadership experience in areas such as people management, client experience, and process improvement. She previously served as president and director of Intelligere, Inc.
Peter Horwich, Vice President, Marketing
Mr. Horwich was appointed Vice President, Marketing in October 2024. He brings more than 20 years of MedTech expertise to Electromed, aiming to accelerate the adoption of SmartVest therapy and expand market reach.
AI Analysis | Feedback
Key Business Risks for Electromed (ELMD)
Electromed, Inc., a company specializing in high-frequency chest wall oscillation (HFCWO) therapy products, faces several key business risks inherent to the medical device industry and its specific market niche.
- Intense Competition: The airway clearance therapy market is highly competitive and fragmented, with Electromed's SmartVest product competing against other established players such as Tactile Medical and Baxter. These competitors may possess stronger brand recognition, technological advantages, and higher growth rates, posing a continuous challenge to Electromed's market share and pricing power.
- Reimbursement Policy Changes: Electromed's financial performance is significantly influenced by healthcare reimbursement policies. Changes to Medicare, Medicaid, or private insurance reimbursement policies, including coverage criteria and payment rates for HFCWO devices, could adversely affect the affordability and adoption of their products, thereby impacting revenue and profitability. The high cost of HFCWO devices can also be a barrier if not adequately reimbursed.
- Efficacy and Alternative Therapies: The long-term demand for Electromed's HFCWO therapy could be impacted by evolving scientific evidence regarding its comparative efficacy against alternative airway clearance methods or by the discovery of new drugs and pharmaceutical treatments. While HFCWO has demonstrated efficacy for conditions like cystic fibrosis and bronchiectasis, ongoing research and the emergence of other effective therapies could shift treatment paradigms, potentially diminishing the perceived necessity or market for HFCWO devices.
AI Analysis | Feedback
nullAI Analysis | Feedback
Electromed, Inc. (ELMD) operates within the airway clearance therapy market, primarily offering High-Frequency Chest Wall Oscillation (HFCWO) systems like the SmartVest. The company targets patients with conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disease.
The company itself estimates a potential total addressable market of $15.1 billion for its products in the U.S.. This figure is derived from an estimated 4.1 million patients multiplied by an assumed HFCWO average selling price of $10,500. Electromed also estimated the size of the U.S. homecare market for HFCWO to be approximately $265 million in 2025.
Here's a breakdown of the addressable markets for Electromed's main products and the diseases they serve:
High-Frequency Chest Wall Oscillation (HFCWO) Devices Market
- The global high-frequency chest-wall oscillation devices market size was valued at approximately USD 2.82 billion in 2024 and is projected to reach around USD 5.57 billion by 2034.
- Another estimate places the global market at $2.65 billion in 2025, expected to grow to $2.86 billion in 2026.
- The global airway clearance systems market, which includes HFCWO, was valued at USD 603.7 million in 2023 and is projected to grow to USD 976.4 million by 2032. North America accounted for a 32.5% share of the global airway clearance systems market in 2023. North America also held the largest share of the global high-frequency chest-wall oscillation devices market.
Bronchiectasis Market
- The global bronchiectasis market size was valued at USD 597.25 million in 2024 and is expected to reach USD 959.14 million by 2032.
- The 7 major bronchiectasis markets (7MM: United States, Germany, France, the United Kingdom, Italy, Spain, and Japan) reached a value of USD 459.4 million in 2024 and are expected to reach USD 766.7 million by 2035.
- In 2023, the total bronchiectasis market size in the 7MM was approximately USD 1,581.2 million, with the U.S. accounting for approximately USD 740.9 million (47% of the total 7MM market revenue).
- North America dominated the bronchiectasis market with the largest revenue share of 39.5% in 2024, and the U.S. bronchiectasis market captured 47.4% of that share within North America. The bronchiectasis therapeutic market in North America is expected to hold a 51% market share.
- The global bronchiectasis drugs market size was valued at USD 1.45 billion in 2025 and is projected to grow to USD 2.67 billion by 2034.
Cystic Fibrosis Market
- The global cystic fibrosis therapeutics market size was calculated at USD 11.81 billion in 2025, grew to USD 13.49 billion in 2026, and is projected to reach around USD 44.72 billion by 2035.
- Another report states the global cystic fibrosis market size stood at USD 5.12 billion in 2019 and is projected to reach USD 62.57 billion by 2032.
- The cystic fibrosis market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Canada) is forecast to grow from USD 11.1 billion in 2024 to USD 16.0 billion in 2034.
- In 2023, the cystic fibrosis market size in the 7MM was approximately USD 18,743 million, with the U.S. accounting for approximately USD 9,473 million.
- North America dominated the cystic fibrosis market with a 75.98% share in 2019. North America also dominated the cystic fibrosis therapeutics market in 2025.
Neuromuscular Disease Therapeutics Market
- The global neuromuscular disease therapeutics market size is forecast to increase by USD 13.73 billion, at a CAGR of 14.6% between 2024 and 2029.
- The neuromuscular disease therapeutics market reached US$ 11.89 billion in 2023, with a rise to US$ 13.70 billion in 2024, and is expected to reach US$ 45.62 billion by 2033.
- The neuromuscular disorders market size is expected to grow from $8.31 billion in 2025 to $8.98 billion in 2026. It is projected to grow to $12.07 billion in 2030.
- North America was the largest region in the neuromuscular disorders market in 2025. North America also dominated the market for neuromuscular disease therapeutics, accounting for a 44% growth during the forecast period (2024-2029).
- The nucleic acid and gene therapies in the neuromuscular disorders market are projected to grow from USD 9.4 billion in 2025 to USD 23.4 billion by 2035.
AI Analysis | Feedback
Electromed (ELMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:- Expanded Direct Sales Force and Enhanced Sales Productivity: Electromed is actively expanding its direct sales force, with plans to increase the number of representatives, and is focused on improving the productivity of these sales personnel. This strategy is anticipated to lead to incremental patient referrals and approvals, thereby boosting direct homecare revenue.
- Targeted "Triple Down on Bronchiectasis" Marketing Campaign: The company has launched a strategic marketing initiative aimed at increasing awareness among physicians and patients regarding the significant, underserved bronchiectasis market. This campaign, which promotes a "3-pronged treatment paradigm," is designed to capture a larger share of the nearly 800,000 diagnosed bronchiectasis patients who could benefit from the SmartVest system.
- Expansion of Payer Coverage: Electromed is continually working to secure new payer contracts, successfully adding millions of covered lives to its potential patient base. For instance, in the first half of fiscal year 2026, the company executed 25 new payer contracts, adding approximately 2.9 million covered lives, which broadens access to their airway clearance therapy products.
- Sustained Growth in Core Homecare and Distributor Channels: The company's core homecare business has demonstrated consistent strong performance, serving as a primary engine for revenue growth. Additionally, the distributor channel has shown robust growth, further extending the reach of Electromed's SmartVest system.
- Operational Efficiencies and Manufacturing Optimization: Electromed has implemented a manufacturing optimization plan and deployed a new CRM system. These operational enhancements are expected to improve overall efficiency, increase manufacturing capacity, and boost sales productivity, ultimately supporting scalable revenue growth and expanded operating leverage.
AI Analysis | Feedback
Share Repurchases- Electromed's board of directors authorized a new share repurchase program of up to $10.0 million on September 9, 2025.
- During fiscal year 2025, Electromed repurchased $10.0 million of its common stock.
- In the six months ended December 31, 2025, approximately $3.8 million of shares were repurchased under the $10.0 million authorization.
- Electromed's issuance of stock for the three months and trailing twelve months ended December 2025 was $0.00 million.
- As of August 20, 2025, there were 8,349,176 shares of common stock outstanding.
- A director acquired 3,000 shares of restricted stock at $0 per share on December 1, 2025, as part of an insider stock award.
- Electromed invested $886,000 in capital expenditures in Q2 2026, marking an increase of 39.7% from the prior quarter.
- Capital expenditures in Q2 2026 totaled $0.63 million, representing a 172.1% increase year-over-year.
- Capital expenditures were reported as $252,000 in a quarter ending December 31, 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Electromed Earnings Notes | 12/16/2025 | |
| How Low Can Electromed Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ELMD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.57 |
| Mkt Cap | 0.9 |
| Rev LTM | 502 |
| Op Inc LTM | 5 |
| FCF LTM | 4 |
| FCF 3Y Avg | -1 |
| CFO LTM | 31 |
| CFO 3Y Avg | 1 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.9% |
| Rev Chg 3Y Avg | 14.0% |
| Rev Chg Q | 16.0% |
| QoQ Delta Rev Chg LTM | 3.6% |
| Op Inc Chg LTM | 52.4% |
| Op Inc Chg 3Y Avg | 37.2% |
| Op Mgn LTM | 8.4% |
| Op Mgn 3Y Avg | 3.9% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 10.6% |
| CFO/Rev 3Y Avg | 5.1% |
| FCF/Rev LTM | 6.4% |
| FCF/Rev 3Y Avg | 3.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 3.4 |
| P/Op Inc | -1.7 |
| P/EBIT | 2.3 |
| P/E | 7.7 |
| P/CFO | 27.0 |
| Total Yield | 0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.3% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 18.4% |
| 3M Rtn | 3.7% |
| 6M Rtn | -19.9% |
| 12M Rtn | -3.2% |
| 3Y Rtn | -7.7% |
| 1M Excs Rtn | 13.5% |
| 3M Excs Rtn | -5.4% |
| 6M Excs Rtn | -31.8% |
| 12M Excs Rtn | -32.4% |
| 3Y Excs Rtn | -90.1% |
Price Behavior
Price Behavior
| Market Price | $38.30 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 08/13/2010 | |
| Distance from 52W High | -0.7% | |
| 50 Days | 200 Days | |
| DMA Price | $27.18 | $25.90 |
| DMA Trend | up | up |
| Distance from DMA | 40.9% | 47.9% |
| 3M | 1YR | |
| Volatility | 62.0% | 52.6% |
| Downside Capture | 41.16 | 99.54 |
| Upside Capture | 213.79 | 146.33 |
| Correlation (SPY) | 23.0% | 23.6% |
ELMD Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.62 | 0.84 | 0.88 | 0.54 | 0.99 | 0.65 |
| Up Beta | -0.08 | 0.01 | -0.12 | 0.06 | 0.74 | 0.67 |
| Down Beta | -1.09 | 0.40 | 0.36 | -0.02 | 0.62 | 0.64 |
| Up Capture | 94% | 145% | 110% | 96% | 115% | 45% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 24 | 34 | 68 | 134 | 370 |
| Down Capture | 472% | 116% | 165% | 89% | 123% | 76% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 19 | 30 | 57 | 115 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELMD | |
|---|---|---|---|---|
| ELMD | 90.6% | 52.7% | 1.40 | - |
| Sector ETF (XLV) | 15.9% | 14.6% | 0.79 | 25.7% |
| Equity (SPY) | 30.3% | 12.0% | 1.91 | 23.3% |
| Gold (GLD) | 36.8% | 26.8% | 1.14 | -4.2% |
| Commodities (DBC) | 41.2% | 18.7% | 1.71 | -18.5% |
| Real Estate (VNQ) | 16.3% | 13.1% | 0.89 | 14.7% |
| Bitcoin (BTCUSD) | -32.5% | 41.9% | -0.83 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELMD | |
|---|---|---|---|---|
| ELMD | 33.2% | 46.4% | 0.77 | - |
| Sector ETF (XLV) | 5.5% | 14.7% | 0.19 | 18.5% |
| Equity (SPY) | 14.3% | 17.0% | 0.66 | 17.5% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | -1.2% |
| Commodities (DBC) | 10.1% | 19.4% | 0.41 | 0.4% |
| Real Estate (VNQ) | 3.9% | 18.8% | 0.11 | 17.6% |
| Bitcoin (BTCUSD) | 12.0% | 55.3% | 0.42 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELMD | |
|---|---|---|---|---|
| ELMD | 26.1% | 53.0% | 0.65 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.47 | 20.9% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 22.3% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 0.6% |
| Commodities (DBC) | 7.5% | 17.9% | 0.34 | 8.1% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 23.0% |
| Bitcoin (BTCUSD) | 66.8% | 66.9% | 1.06 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 02/10/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/26/2025 | 10-K |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/11/2025 | 10-Q |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/27/2024 | 10-K |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/22/2023 | 10-K |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/23/2022 | 10-K |
Recent Forward Guidance [BETA]
Latest: Q3 2026 Earnings Reported 5/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Annualized homecare revenue per weighted average direct sales representative | 1.00 Mil | 1.05 Mil | 1.10 Mil | 0 | Affirmed | Guidance: 1.05 Mil for 2026 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Skarvan, Kathleen | Direct | Sell | 5192026 | 35.48 | 40,000 | 1,419,358 | 1,264,009 | Form | |
| 2 | Summers, Andrew | SPV Deal Fund I LP | Sell | 9122025 | 24.42 | 3,153 | Form | |||
| 3 | Summers, Andrew | SVP Deal Fund I LP | Sell | 9122025 | 23.71 | 39,782 | 943,192 | 74,755 | Form | |
| 4 | Summers, Andrew | SPV Deal Fund I LP | Sell | 9122025 | 25.39 | 22,779 | 578,261 | 90,297 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.